34 results about "Endometrosis" patented technology

The invention discloses a protein marker for treating endometriosis. Specifically, the protein marker is PGR. The invention also discloses application of a PGR gene in the preparation of a product fortreating endometriosis, a pharmaceutical composition for treating endometriosis and a kit for evaluating the expression level of the PGR gene. The pharmaceutical composition disclosed by the invention has a relatively good inhibition effect on endometriosis, and has important reference and practical significance in endometriosis treatment. The kit provided by the invention can be used as one of evaluation means of the PGR gene expression level, and has good measurement and guidance effects when PGR is used as a pharmaceutical composition.

The invention relates to a medicine for treating endometriosis, in particular to a Chinese medicine oral decoction for treating endometriosis, which is prepared by using Chinese herbal medicines as raw materials. The invention adopts the technical scheme that the Chinese medicine oral decoction comprises the following raw medicinal materials in parts by weight: 4-12g of bupleurum, 4-12g of salvia miltiorrhiza, 4-12g of achyranthes, 5-15g of red paeony roots, 5-15g of pollen typhae, 5-15g of hemlock parsley, 5-15g of barbary wolfberry fruits, 5-15g of herba epimedii and 5-15g of Chinese dodder seeds. In the invention, all the raw medicinal materials are reasonably mixed to achieve the efficacies of promoting blood circulation and removing blood stasis, clearing heat and detoxicating, relieving stasis and stopping pain, removing heat from the blood and dispersing swelling, calming the mind, relaxing bowel, and the like. By oral administration, the Chinese medicine oral decoction can regulate inner body, strengthen the body resistance to consolidate the constitution, regulate endocrine disturbance, enhance immune functions of human bodies, balance yin and yang, restore the Zang-Fu functions in dynamic balance, and effectively treat endometriosis. The invention has the advantages of no side effect, economy, practicability and simple method, and can be prepared independently. The invention is applicable to patients with slight endometriosis accompanied with luteal insufficiency or ovulation failure.

The invention relates to detection of individuals having or at risk of developing endometriosis based on the presence of one or more polymorphism in a gene associated with the fibrinolytic pathway, and methods for treating or preventing endometriosis by modulating the fibrinolytic pathway.

The invention provides a traditional Chinese medicine composition for treating endometriosis and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The invention relates to a traditional Chinese medicine composition for treating endometriosis. The traditional Chinese medicine composition is prepared from the following raw materials: Salvia pachysandra, Semen et Herba Lysimachiae, evergreen mucuna root and leaf, ground beetle, rape seed, Artemisia anomala, Salvia chinensis, Rhodiola rosea, Glycyrrhiza foenum-graecum, Polygonum hydropiper root, Rhizoma Corydalis, processed Rhizoma Cyperi, Fructus Toosendan and honey-fried licorice root. The medicine prepared by the invention has the comprehensive effects of promoting blood circulation to remove blood stasis, warming meridians to relieve pain, eliminating mass and resolving masses and tonifying kidney and spleen, promotes blood stasis to dissolve and internally eliminate so as to achieve smoothness, has a unique curative effect on dysmenorrhea, infertility, abdominal mass accumulation and other symptoms caused by endometriosis, can reduce the relapse rate, has an obvious long-term treatment effect and small toxic and side effects, and has a remarkable improvement effect on liver depression and qi stagnation andobstruction of collaterals by blood stasis, and therefore, the traditional Chinese medicine composition has a very good effect on treating the disease.

Provided is a method of non-invasively diagnosing endometriosis in a subject comprising maintaining or culturing stromal cells, obtained from a menstrual effluent or discharge sample from the subject. Also provided is a method of non-invasively diagnosing fertility in a subject. Also provided is a kit for non-invasively diagnosing endometriosis in a subject. Also provided is a method of treating endometriosis in a subject. Also provided is a method of preventing the progression or development of endometriosis in a subject.

The present invention provides a method of diagnosing endometriosis and / or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and / or protein in the sample; c) detecting a level of expression of a BCL6 gene and / or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and / or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and / or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and / or protein greater than the level of expression of the SIRT1 gene and / or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and / or protein that is greater than the level of expression of the BCL6 gene and / or protein of the control subject or population of control subjects.

Provided herein are monoclonal antibodies with a high binding affinity to isoforms of alpha 1-antitrypsin (A1AT), hybridoma cells producing the same, and their uses in diagnosing and / or detecting endometriosis from a serum sample of a subject suspicious of having endometriosis or a subject under health examination.

In some aspects, the disclosure relates to methods for screening clinical samples for the presence of L-form bacteria associated with endometriosis and / or ovarian fibroid tumors. The disclosure is based, in part, on screening methods used to diagnose a subject as likely having or likely not having endometriosis and / or an ovarian fibroid tumor. In some embodiments, the disclosure relates to methods of treating endometriosis by administering an antibiotic to a subject that has been determined to be infected by one or more strains of L-form bacteria.

The invention discloses the application of endometriosis serum markers in the preparation of endometriosis screening and diagnosis products, belonging to the technical field of biomedicine. The endometriosis serum markers are blood vessels Tensinogen (AGT) and / or sclerostin domain protein 1 (SOSTDC1). When AGT and SOSTDC1 were used as targets for the detection of serum proteins, both had high sensitivity and specificity, so they could be used as screening targets for endometriosis.

Use of serum microvesicle-asparagine endopeptidase pseudogene 1 in the preparation of a biomarker for diagnosing endometriosis or predicting the recurrence of endometriosis, serum microvesicle-asparagine endopeptide The gene sequence of the enzyme pseudogene 1 is shown in SEQ ID NO.1. Also provided is a kit for diagnosing endometriosis or predicting the recurrence of endometriosis, containing reagents for detecting EV-LGMNP1, including upstream primer sequences, downstream primer sequences and probes, the sequences of which are as shown in SEQ ID NO.5-7. It was found that EV-LGMNP1 could be detected in the serum of patients with endometriosis, and its expression level was significantly higher than that of women without endometriosis, and its expression was significantly increased in patients with recurrent endometriosis. Novel non-invasive biomarkers for the diagnosis of endometriosis, prediction of endometriosis recurrence, and condition monitoring.

The present invention relates to a method of assessing whether a patient has or is at risk of developing endometriosis by determining the amount or concentration of S100A8 in a sample of the patient and comparing the determined amount or concentration to a reference, a method of selecting a patient for therapy, and methods of monitoring a patient suffering from endometriosis or being treated with endometriosis.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A8 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to a method of assessing whether a patient has or is at risk of developing endometriosis by determining the amount or concentration of S100A6 in a sample of the patient and comparing the determined amount or concentration to a reference, a method of selecting a patient for therapy, and methods of monitoring a patient suffering from endometriosis or being treated with endometriosis.

The invention belongs to the technical field of medicine, and relates to application of a hydrogen sulfide synthetase inhibitor PAG in preparation of medicines for treating endometriosis (EMS). The invention evaluates the potential value of the hydrogen sulfide synthetase inhibitor PAG in the treatment of the EMS through experimental research; the results show that the expression level of hydrogensulfide synthetase CSE in the ectopic endometrium of a patient with the EMS is higher than that of the hydrogen sulfide synthetase CSE in normal endometrium, thus suggesting that hydrogen sulfide participates in the disease progression of the EMS; sodium hydrosulfide significantly promotes the proliferation of endometrial stromal cells (ESC), but the hydrogen sulfide synthetase inhibitor PAG significantly inhibits the growth of ectopic foci. The results prove that the hydrogen sulfide synthase inhibitor PAG can be used for the preparation of the medicines for treating the EMS. The invention provides a new pharmaceutical use of the hydrogen sulfide synthetase inhibitor PAG, thus providing a new method and a new idea for the clinical treatment of the EMS.

The present invention relates to the use of pyrroloquinoline quinine (PQQ), its derivatives and / or salts for the preparation of drugs for the treatment and / or prevention of endometriosis including adenomyosis, chocolate cyst of ovary, deeply infiltrating endometriosis and other type of endometriosis. In addition, the present invention relates to the use of PQQ in combination with one or more the following antioxidants: N-Acetyl-L-cysteine (NAC), resveratrol, epigallocatechin gallate, vitamin E or vitamin C for the preparation of drugs for inhibiting the proliferation, oxidative stress status, invasion and migration of endometrial stromal cell. The use of PQQ in combination with NAC shows a synergistic effect on inhibiting cell proliferation: significantly inhibiting the proliferation of endometrial stromal cell in vitro; significantly reducing the damaged size of tissue caused by endometriosis in vivo; significantly reducing the infiltration of endometrial stroma and glands; significantly reducing the dose of NAC as well. PQQ is beneficial for fertility, and increases the chances of getting pregnant. PQQ alone or PQQ in combination with NAC generally shows no side effects and will not interfere with pregnancy.

The invention discloses an application of an FGFR2c extracellular domain analogue in preparation of a medicine for preventing and treating endometriosis, and the FGFR2c extracellular domain analogue has a good effect of reducing the size of a mouse endometriosis focus and the fibrosis area, and is superior to that of a gestotrione group. A new means is provided for clinically preparing medicines for treating endometriosis and all diseases related to fibrosis.

The invention relates to a traditional Chinese medicine monomer for treating early endometriosis and application thereof. The traditional Chinese medicine monomer is ginsenoside Rg3. Results show thatthe ginsenoside Rg3 can inhibit angiogenesis of ectopic endometrium of an endometriosis rat, but does not affect the form of the endometrium in situ, which indicates that physiological blood vesselsare not affected by the ginsenoside Rg3, so that the ginsenoside Rg3 has extremely low toxicity to normal tissues. Therefore, the ginsenoside Rg3 can be applied to early treatment of endometriosis andtreatment of residual lesions in laparoscopic surgery to prevent relapse without hindering ovulation, and conforms to ideal drugs for early treatment and prevention of endometriosis. In addition, ginsenoside Rg3 can obviously lower the level of serum E2 of rats suffering from endometriosis, but has no obvious influence on the serum P level, so that the ginsenoside Rg3 is prompted to adjust the in-vivo endocrine environment by adjusting the in-vivo hormone level, does not affect pregnancy while treatment diseases, is the most effective treatment for EMs, and is high in practicability.

The invention provides a traditional Chinese medicine monomer for treating endometriosis. Treatment medicines comprise the traditional Chinese medicine monomer and compound medicine-containing serum.The traditional Chinese medicine monomer comprises cinnamyl aldehyde. The compound medicine-containing serum is made of traditional Chinese medicines including lignum dalbergiae odoriferae, lignum aquilariae resinatum, radix cyathulae and faeces trogopterori. The traditional Chinese medicine monomer has the advantages that proliferation of interstitial cells at ectopic foci of the endometriosis can be obviously inhibited by the traditional Chinese medicine monomer at in-vitro cell levels, certain effects of promoting apoptosis of the interstitial cells at the ectopic foci of the endometriosiscan be realized by the traditional Chinese medicine monomer, the traditional Chinese medicine monomer can be used for developing medicines for the endometriosis, and endometriosis treatment auxiliaryenhancement effects for the traditional Chinese medicine monomer can be realized by the medicine-containing serum.

A circulating exosome long-chain non-coding RNA-TC0101441 is used as a marker for diagnosing endometriosis, and the gene sequence of the circulating exosome long-chain non-coding RNA-TC0101441 is as shown in SEQ ID NO.1 Show. Provided is a kit for diagnosing endometriosis, which contains a reagent for detecting circulating exosome long non-coding RNA-TC0101441, the reagent includes an upstream primer sequence and a downstream primer sequence, and the upstream primer sequence is as shown in SEQ ID NO .2, the downstream primer sequence is shown in SEQ ID NO.3. The present invention found that exosome TC0101441 can be detected in the serum of patients with endometriosis, and its expression level is significantly higher than that of women without endometriosis. Invasive biomarkers.

The invention belongs to the technical field of medicines, and relates to an application of a hydrogen sulfide synthase inhibitor AOAA (aminooxyacetic acid) to preparation of a medicine for treating endometriosis. The potential value of the hydrogen sulfide synthase inhibitor AOAA in treatment of EMS (endometriosis) is evaluated by experimental study, results display that the expression level of hydrogen sulfide synthase CBS in an ectopic endometrium of an EMS patient is higher than that of a normal endometrium, participation of hydrogen sulfide in the disease progression process is prompted,sodium hydrosulfide obviously promotes ESC (endometrial stromal cell) proliferation, and growth of an ectopic focus is remarkably inhibited by the hydrogen sulfide synthase inhibitor AOAA. The resultsindicate that the hydrogen sulfide synthase inhibitor AOAA can be used for preparing the medicine for treating the endometriosis. The new pharmaceutical application of the hydrogen sulfide synthase inhibitor AOAA is provided, and a new method and a new idea are provided for clinic treatment of the EMS.

The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.

The invention relates to a biomarker, a kit and a method for diagnosing endometriosis, and concretely provides a use of a monoclonal antibody binding to a specific antigen on a circulating endometrialcell in the preparation of the kit for diagnosing endometriosis.

The present invention relates to isolated ligands of anti-Mullerian hormone marked so as to be directly detectable by means of magnetic resonance imaging in the endometriosic lesions. In particular, such ligands can be used in a method for diagnosing in vivo endometriosis wherein said method comprises a passage of localizing and / or evaluating the entity of the endometriosic lesions in a patient.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A6 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to the use of pyrroloquinoline quinine (PQQ), its derivatives and / or salts for the preparation of drugs for the treatment and / or prevention of endometriosis including adenomyosis, chocolate cyst of ovary, deeply infiltrating endometriosis and other type of endometriosis. In addition, the present invention relates to the use of PQQ in combination with one or more the following antioxidants: N-Acetyl-L-cysteine (NAC), resveratrol, epigallocatechin gallate, vitamin E or vitamin C for the preparation of drugs for inhibiting the proliferation, oxidative stress status, invasion and migration of endometrial stromal cell. The use of PQQ in combination with NAC shows a synergistic effect on inhibiting cell proliferation: significantly inhibiting the proliferation of endometrial stromal cell in vitro; significantly reducing the damaged size of tissue caused by endometriosis in vivo; significantly reducing the infiltration of endometrial stroma and glands; significantly reducing the dose of NAC as well. PQQ is beneficial for fertility, and increases the chances of getting pregnant. PQQ alone or PQQ in combination with NAC generally shows no side effects and will not interfere with pregnancy.

Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A12 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of Substance P in a sample of the patient, and comparing the determined amount or concentration to a reference.